ULTRA-BNCT07928427
Comparing Ultrafractionated and Moderate Hypofractionated Radiotherapy for Post-Surgery Breast Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Local-Regional Recurrence (LRR)
Timeframe: 5 years
Secondary (8)
Acute and Late Toxicities
Overall Survival (OS)
Disease-Free Survival (DFS)
Distant Metastasis-Free Survival (DMFS)
Breast Cancer-Specific Survival (BCSS)
Show 3 moreShow less
EORTC Quality of Life Questionnaire (EORTC-QLQ-C30; version 3)
breast cancer module (QLQ-BR23)
the Quick Disabilities of the Arm, Shoulder and Hand (q-DASH) questionnaire.
Arms and interventions
Ultrafractionated RadiotherapyExperimental
26Gy in 5 fractions to the breast/chest wall with or without regional nodal irradiation. For breast-conserving surgery patients, a simultaneous integrated boost (SIB) of 31Gy in 5 fractions is delivered to the tumor bed.
Moderately Hypofractionated RadiotherapyActive comparator
40Gy in 15 fractions to the breast/chest wall with or without regional nodal irradiation. For breast-conserving surgery patients, a simultaneous integrated boost (SIB) of 48Gy in 15 fractions is delivered to the tumor bed.
Radiation: Ultrafractionated Radiotherapy, Moderately Hypofractionated Radiotherapy
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China